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“The important thing is not to stop questioning” 
 
- Albert Einstein (1879-1955) 
ABSTRACT 
The genome of eukaryotic cells is stored in the nucleus as chromatin, a DNA-protein 
complex that serves to compact and protect the DNA molecules. The basic unit of 
chromatin is the nucleosome composed of DNA wrapped around a histone protein core. 
In addition to condensing and protecting the genome, chromatin confers a number of 
regulatory properties employed for example in control of gene expression and 
stabilization of repetitive sequences. Chromatin also constitutes an obstacle that needs 
to be negotiated in processes such as transcription elongation, DNA replication and 
DNA repair. A wide range of chromatin modifying factors and mechanisms are 
involved in regulating the state of chromatin and affect all DNA related processes. 
These mechanisms, often referred to as epigenetic, include methylation of DNA, 
regulation by non-coding RNAs, remodeling of nucleosomes, posttranslational 
modifications of histones and incorporation of variant histones. The resulting chromatin 
state is called the epigenome and can, in contrast to the underlying DNA sequence, 
differ between cells in the same organism.  
 
This thesis describes characterization of aspects of the egipenomes of hematopoietic 
cells and fission yeast. We show that in fission yeast, genes with related functions share 
common patterns of histone modifications in the promoter regions. We also 
demonstrate crosstalk between different histone modifications, including 
interdependence of histone H4 acetylation sites and regulatory roles of histone 
methylation for histone acetylation.  
 
To better understand how chromatin factors influence human blood development we 
analysed expression of genes encoding chromatin modifying proteins in the 
hematopoietic system, including the hematopoietic stem cells and a wide range of 
mature blood cells. In doing so we could identify epigenetic factors that were expressed 
in cell type, cell lineage or cancer specific patterns, implicating them in regulation of 
blood development. We also found that several genes display differential use of 
alternative transcription start sites between cell types.  
 
Finally we constructed an in-depth map of how DNA methylation and gene expression 
changes during human granulocyte development. Our experiments show that DNA 
methylation changes are linked to points of lineage restriction, implicating DNA 
methylation in control of cell fate. DNA methylation changes, most of which were 
decreases, were primarily located outside of CpG islands, which have been the focus of 
most DNA methylation studies historically. Interestingly, DNA methylation was 
especially dynamic in enhancer elements, and sites with decreasing DNA methylation 
overlapped with differentiation induced enhancers and increased expression of target 
genes. This result suggests a role of DNA methylation in regulating enhancer activity in 
granulopoiesis. 
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1 INTRODUCTION 
 
1.1 CHROMATIN 
A human cell contains approximately two meters of DNA stored in a nucleus with a 
diameter of around six micrometres. For this to be possible, the genome must be 
efficiently compacted and organized to avoid physical damage. At the same time, DNA 
sequences such as genes and other functional loci must remain accessible upon 
demand. These requirements are fulfilled through packing the genome of eukaryotic 
cells in the form of chromatin, a complex of equal amounts of DNA and proteins. 
Chromatin organizes the genome into structures of varying compaction, the most 
extreme of which is the condensed metaphase chromosome. The first level of 
compaction consists of DNA wound around a core of histone proteins creating the 
nucleosome. 
 
There are several forms of specialized chromatin. Heterochromatin is highly compacted 
and generally silent and includes for example certain repetitive regions and the silent X-
chromosome. Euchromatin, on the other hand, is less compact and general more 
transcriptionally active while the specialized centromeric heterochromatin is crucial for 
chromosome segregation. 
 
In addition to condensing and organizing the DNA in the nucleus, chromatin also 
contributes to regulation of DNA-related processes. Indeed, basically all DNA-related 
processes, including replication, repair and transcription, must take place in the context 
of chromatin, putting high demands on regulated accessibility.  
 
Epigenetics has been defined as heritable changes in gene expression without changes 
to the underlying DNA sequence (Russo et al, 1996), but is commonly used to describe 
changes in chromatin state (Bird, 2007). Epigenetic mechanisms include addition and 
removal of posttranslational modifications to histones, incorporation of histone 
variants, rearrangement of nucleosomes by chromatin remodeling enzymes, 
methylation of DNA and regulation by non-coding RNA. These mechanisms of 
modifying chromatin play a central role in regulating chromatin states and functions. 
Epigenetics is recognized as an important determinant in normal development and 
differentiation, and epigenetic abnormalities are relevant in many diseases, including 
various malignancies. 
 
1.2 THE NUCLEOSOME AND HISTONES 
The basic unit of chromatin is the nucleosome, consisting of 146 bp wrapped 1.65 turns 
around a histone octamer core (Luger et al, 1997) (Figure 1A). Individual nucleosomes 
are connected by short stretches of DNA, called linker DNA, into nucleosomal arrays 
resembling beads on a string when viewed by electron microscopy. Nucleosomal arrays 
are further organized into chromatin fibres of increasing compaction, the most extreme 
of which is the metaphase chromosome.  
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The histone octamer core of the nucleosome consists of two copies each of histones 
H2A, H2B, H3 and H4. These small basic proteins possess a conserved “histone fold” 
structure with three alpha helices connected by two loops.  Histones assemble into 
H2A-H2B and H3-H4 dimers. In the nucleosome two H3-H4 dimers form a central 
tetramer flanked by two H2A-H2B dimers (Luger et al, 1997). The unstructured N- 
and C-terminal tails of the histones extend from the nucleosome and are involved in 
interactions with neighbouring nucleosomes and other proteins. Linker histones, 
exemplified by histone H1, bind to the linker DNA and facilitate formation of higher 
order chromatin structures. The stability of the nucleosome is affected by several 
factors such as the underlying DNA sequence and the specific composition and 
modifications of the histone core. 
 
1.2.1 Histone variants 
The canonical histones are expressed and incorporated in a replication dependent 
manner. In addition to these, there are also a number of histone variants whose 
expression is replication independent. Most variants are for H2A and H3 and many are 
conserved between species (Talbert & Henikoff, 2010). The histone variants differ 
from their major-type counterpart in the amino acid sequence giving them unique 
properties and several have been associated with specific functions and locations in 
chromatin. For example, centromere specific H3 variants (CenH3) occupy centromeric 
chromatin and are required for kinetochore assembly (Talbert & Henikoff, 2010). 
H2A.Z has a conserved localization at 5´-ends of genes (Mavrich et al, 2008; Li et al, 
2005; Zilberman et al, 2008; Barski et al, 2007), and is believed to be involved in, 
among other processes, transcription regulation. However, the precise effect seems to 
depend of the species/cell type and on posttranslational modifications (Li et al, 2005; 
Barski et al, 2007; Talbert & Henikoff, 2010; Millar, 2013). The histone variant 
H2A.X is highly similar to canonical H2A, but has a C-terminal serine that is 
phosphorylated at the site of double strand DNA lesions and is thought to recruit and/or 
retain repair machinery (Talbert & Henikoff, 2010). 
 
1.3 HISTONE MODIFICATIONS 
Histones are subject to a multitude of posttranslational modifications, most famously 
acetylation, methylation, phosphorylation, sumoylation and ubiquitination (Figure 1B). 
Recently several new histone modifications and modification sites have been 
discovered (Tan et al, 2011b), but in many cases the function of these novel 
modifications remains to be tested. Histones are preferentially modified on the 
protruding N-terminal tails, although some modifications localize to the globular 
domains. Histone modifications affect many aspects of chromatin biology including 
DNA repair, chromatin compaction, transcription initiation and elongation.  
 
Considering the high number of different histone modifications and modification sites, 
the potential complexity is enormous. Histone modifications have been proposed to 
constitute a histone code where specific combinations of modifications give rise to 
specific effects in chromatin (Strahl & Allis, 2000). The histone code theory has been 
debated and several objections have been raised against it. Most importantly the limited 
complexity of observed modification patterns is argued to be incompatible with a true 
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code (Rando, 2012). Nevertheless, sets of modification patterns preferentially 
associated with genes of specific functional classes have been reported (Kurdistani et 
al, 2004). 
 
This section will focus on acetylation and methylation of lysine residues, two of the 
best characterized types of histone modifications, and the enzymes involved in 
catalyzing their addition to and removal from histone substrates. 
 
 
 
 
Figure 1 Histone modifications 
A) Schematic picture of nucleosomes. DNA (black) is wound 1.65 turns around a histone protein core 
(blue) composed of two copies of histone H2A, H2B, H3 and H4. The unstructured histone tails protrude 
from the nucleosomes. 
B) Histone tails, in particular the N-terminal tails, but also the globular domains, are subject to a plethora 
of posttranslational modifications. This picture shows some of the better known sites for acetylation (A), 
methylation (M), phosphorylation (P) and ubiquitination (U). In addition, histones may be modified by 
sumoylation, ADP-ribosylation, glycosylation, crotonylation, formylation, glycosylation, succinylation, 
oxidation and propionylation. 
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1.3.1 Histone acetylation, KATs and HDACs 
The basic N-terminal tails of histones contain multiple lysine residues and lysine 
acetylation is one of the most studied histone modifications. Histone acetylation and 
methylation was described already in 1964 (Allfrey & Mirsky, 1964). Since then 
acetylation of non-histone proteins has also gained interest and is believed to be as 
extensive and important to cellular biology as protein phosphorylation (Kouzarides, 
2000). 
 
Despite the early description of histone acetylation, the enzymes adding and removing 
this mark were not discovered until 1995 (Kleff et al, 1995; Brownell & Allis, 1995; 
Taunton et al, 1996). Histone, or lysine, acetyltransferases (KATs) catalyze the transfer 
of an acetyl group from acetyl-CoA to the ε-amino group of lysines. Type A KATs 
constitute a diverse family that reside within the nucleus and can be classified into three 
groups: GNAT, MYST and CBP/p300 (Bannister & Kouzarides, 2011). The type B 
KATs are highly conserved and related to budding yeast Kat1p. Type B KATs are 
mainly cytoplasmic and acetylate free/newly synthesized histones on primarily H4K5 
and H4K12 (Parthun, 2007). This modification is important for histone incorporation 
into chromatin, after which the mark is removed. Removal of acetyl groups is catalyzed 
by histone deacetylases (HDACs). There are four classes of HDACs. Class I, II and VI 
require zinc for catalytic activity while the class III HDACs, called sirtuins based on 
homology to yeast Sir2p, are NADH-dependent. 
 
Acetylation is dynamic and the precise acetylation levels result from the opposing 
activities of KATs and HDACs, which often localize to the same sites simultaneously 
or even interact physically to maintain acetylation balance. Although there is some 
variation depending on the precise lysine residue involved, acetylation is generally 
considered to be an active mark present at open chromatin and at promoters of 
transcribed genes (Bannister & Kouzarides, 2011; Wang et al, 2008). Similarly, many 
KATs are considered to be coactivators and many HDACs corepressors (Bannister & 
Kouzarides, 2011). The effect of acetylation on chromatin is likely mediated by both 
the neutralization of the positive charge of lysines decreasing the interaction strength 
with DNA (Zentner & Henikoff, 2013; Hong et al, 1993) and by recruitment of 
proteins and complexes containing a bromodomain that specifically recognize and bind 
acetyllysines (Peserico & Simone, 2011). Bromodomains are present in many proteins 
and protein complexes including chromatin modifiers such as KATs, lysine methyl 
transferases (KMTs), chromatin remodeling complexes (CRCs), and components of the 
general transcription factor TFIID (Filippakopoulos & Knapp, 2012). Interstingly, 
H4K16ac appears to be directly involved in regulating chromatin compaction, as it 
disrupts formation of higher order chromatin structures (Shogren-Knaak et al, 2006).  
 
1.3.2 Histone methylation, KMTs and KDMs 
Histones can be methylated at both lysine and arginine residues, although lysine 
methylation is more extensively studied. In contrast to acetylation, lysines can be 
mono-, di- or trimethylated. The state of methylation impacts on the biological 
outcome, adding an additional level of complexity and regulation (Bannister & 
Kouzarides, 2011). 
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Lysine methyltransferases (KMTs) transfer a methyl group from S-adenosyl 
methionine (SAM) to the lysine ε-amino group (Bannister & Kouzarides, 2011). While 
all KMTs that act on the N-terminal histone tails have a common SET-domain, DOT1, 
which catalyses H3K79 methylation on the globular domain, does not and is 
structurally distinct from other KMTs (Greer & Shi, 2012; Feng et al, 2002). Most 
KMTs function in multisubunit complexes that target the H3 N-terminal tail and 
display a high level of specificity, both regarding the lysine site and the level of 
methylation (Butler & Dent, 2013; Bannister & Kouzarides, 2011). For example, 
humans have several H3K4 KMTs. SETD7 (KMT7) can only monomethylate H3K4 
(Xiao et al, 2003; Wang et al, 2001). Other KMTs such as the MLL1-4 (KMT2A-D), 
SETD1A (KMT2F) and SETD1B (KMT2G) are able to catalyse mono-, di- and 
trimethylation of the same site (Greer & Shi, 2012).  
 
Lysine demethylases (KDM) were discovered relatively recently. The earliest one to be 
described was lysine-specific demethylase 1 (LSD1 or KDM1A), which was first found 
in 2004 (Shi et al, 2004). This enzyme uses flavin adenosine dinucleotide (FAD) as a 
cofactor (Shi et al, 2004) and has different specificities depending on the complex it 
associates with. In the context of the CoREST corepressor complex LSD1 demethylates 
H3K4, while acting as a H3K9 demethylase when interacting with the androgen 
receptor (Klose & Zhang, 2007). As methylation of these sites have opposite effects on 
gene expression, LSD1 can have dual functions as both an activator and a repressor.  
 
While the discovery of LSD1 was a major advance, this enzyme is only capable of 
removing mono- and dimethylation (Shi et al, 2004). Enzymes active on trimethylated 
lysines were not found until 2006, when the Jumonji demethylase family was 
discovered (Tsukada et al, 2005; Whetstine et al, 2006). These enzymes have a 
jumonji domain that is able to remove trimethylation using Fe(II) and α-ketoglutarate 
(α-KG) as cofactors (Whetstine et al, 2006). As KMTs, demethylases have high 
substrate specificity (Bannister & Kouzarides, 2011). 
 
Unlike acetylation the addition of a methyl group does not change the charge of the 
histone protein. Futhermore, in contrast to acetylation, methylation has been strongly 
associated with both transcriptional activation and repression depending on the precise 
lysine site modified. For example, promoter H3K4me3 is strongly correlated with 
active gene expression (Barski et al, 2007; Justin et al, 2010) while H3K9me2/3 is a 
repressive mark that recruits heterochromatin protein 1 (HP1) and is pivotal in 
heterochromatin formation (Lachner et al, 2001; Bannister & Kouzarides, 2011). 
H3K27me3 is another repressive methylation mark that is added and read by 
polycomb-group proteins (PcG). H3K27 is methylated by the polycomb repressive 
complex 2 (PRC2), which includes the KMT EZH2 (KMT6). H3K27me3 is 
subsequently recognized and bound by PRC1 leading to transcriptional silencing and 
chromatin compaction (Simon & Kingston, 2013). 
 
Some promoters show patterns of overlapping H3K4me3 and H3K27me3, commonly 
referred to as bivalent domains (Bernstein et al, 2006). Originally described in 
embryonic stem cells (ESC), bivalent promoters are often associated with genes 
involved in cell fate determination and differentiation (Bernstein et al, 2006). The 
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bivalent domains are believed to keep genes in a state that is transcriptionally silent, but 
poised for activation. 
 
1.3.3 Crosstalk between histone modifications 
There is significant crosstalk between different histone modifications, either in situ (the 
same site), in cis (of the same histone) or in trans (between different histone 
molecules). Both lysine and arginine can be modified in more than one way. Lysines 
for example may be acetylated, methylated, sumoylated or ubiquitinated, depending on 
the site (figure 1B). Since these modifications are mutually exclusive on the same 
lysine residue, it represents the most direct version of crosstalk. Importantly, various 
modifications of a particular site are commonly involved in different or even opposite 
processes. While H3K9me3 is associated with heterochromatin, H3K9ac is found at 
transcribed genes (Lachner et al, 2001; Bannister & Kouzarides, 2011; Wang et al, 
2008). H3K36ac is common in active promoters while H3K36 is methylated in 
transcribed coding regions (Barski et al, 2007; Carrozza et al, 2005; Wang et al, 
2008).  
 
There are several examples of histone modifications at separate sites on the same 
histone affecting each other in cis. H3S10 phosphorylation is believed to cause 
acetylation of H3K14 (Edmondson, 2002) but blocks acetylation of H3K9 (Latham & 
Dent, 2007). Acetylation of histone H4 follows a pattern dubbed the “acetylation zip” 
for K16, K12, K8 and K5 (Turner et al, 1989; Zhang et al, 2002; Tweedie-Cullen et 
al, 2012). These lysines are acetylated from the globular domain and outward (i.e. first 
K16, then K12 etc.) suggesting some mode of crosstalk in cis. Crosstalk in trans tends 
to be somewhat more complicated. One well-know example is the requirement of 
H2BK120 ubiquitination (H2BK123 in budding yeast), for methylation of H3K4 and 
H3K79 in gene bodies during transcription (Latham & Dent, 2007). Another potential 
crosstalk in trans may be mediated through the physical interaction of the H3K4 KMT 
MLL (MLL1/KMT2A) and the KAT MOF (KAT8), possibly linking H3K4me and H4 
acetylation (Dou et al, 2005). 
 
1.4 CHROMATIN REMODELING COMPLEXES 
Chromatin remodeling complexes (CRCs) utilize the energy of adenosine triphosphate 
(ATP) hydrolysis to regulate the structure of nucleosomal chromatin (Hargreaves & 
Crabtree, 2011; Clapier & Cairns, 2009). CRCs perform remodeling by evicting, 
rearranging or sliding nucleosomes along DNA and some are involved in replacing 
canonical histones with histone variants (Clapier & Cairns, 2009). These complexes 
participate in spacing nucleosomes after replication and moving them to allow passage 
of polymerases during transcription and replication, as well as ensuring access of the 
repair machinery upon DNA damage (Narlikar et al, 2013; Clapier & Cairns, 2009; 
Hargreaves & Crabtree, 2011). Remodelers also have regulatory functions by adjusting 
nucleosome positions to hide or expose DNA elements functioning as recognition sites 
(Clapier & Cairns, 2009; Hargreaves & Crabtree, 2011; Narlikar et al, 2013). 
 
The catalytic subunits of CRCs share a DNA-dependent ATPase domain related to the 
yeast Snf2-helicase (Ryan & Owen-Hughes, 2011) and CRCs can be divided into four 
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main families based on the sequence of the ATPase subunit (Flaus, 2006; Clapier & 
Cairns, 2009). Although the INO80, CHD, SWI/SNF and ISWI families all contain the 
Snf2-related ATPase domain, they are distinguishable by the flanking domains (Flaus, 
2006; Clapier & Cairns, 2009). The SWI/SNF ATPases, for example, have a C-
terminal bromodomain, allowing for recognition of acetylated lysines, while the CHD 
remodelers contain N-terminal tandem chromodomains for methyllysine recognition 
(Clapier & Cairns, 2009).  
 
As with other chromatin modifiers most CRC ATPases are incorporated into large 
multimeric complexes, the precise functions of which often depend on subunit 
composition. Accessory subunits are involved in regulating ATPase activity, interacting 
with other chromatin modifying factors or transcription factors and targeting for 
example to specifically modified histones (Narlikar et al, 2013; Clapier & Cairns, 
2009). CRCs have both overlapping and specific functions in chromatin biology, and 
the precise division of labor has not been completely elucidated.  
 
Many CRCs have been shown to be required for normal development. One example is 
the SWI/SNF BAF (BRG1 associated factor) complex. Mammalian BAF complexes 
include one of the ATPase subunits SMARCA4 (BRGI1) or SMARCA2 (BRM) 
(Wang et al, 1996b). Smarca4 is an essential gene in mice (Bultman et al, 2000), while 
Smarca2 mutation causes growth abnormalities (Reyes et al, 1998). Interestingly, BAF 
subunit composition has in many cases been shown to be specific for cell type or 
developmental stage, and subunit replacement may be involved in driving 
differentiation. For example, mouse embryonic stem cells (ESCs) have a specific BAF 
complex that is required for pluripotency (Ho et al, 2009). Similarly, one study showed 
that proliferation of neuronal progenitors requires BAF subunits BAF45a and BAF53a 
(Lessard et al, 2007). Transition into postmitotic neuronal cells was accompanied by 
replacement by these subunits by BAF53b, BAF45b and BAF45c and this switch was 
important for normal differentiation. 
 
1.5 DNA METHYLATION 
DNA can be methylated on the 5-carbon of cytosines, creating 5-methyl cytosine 
(5mC). The most common form of methylation is on cytosines in CpG dinucleotides, 
although significant non-CpG methylation has been reported in ESC (Ramsahoye et al, 
2000; Lister et al, 2009) and in murine frontal cortex (Xie et al, 2012). CpG 
dinucleotides are significantly underrepresented in the genome, possibly because of the 
vulnerability of 5mC to deamination transforming it to thymine and leading to a 
possible C to T mutation (Jones, 2012).  
 
In addition, CpGs are unevenly distributed in the genome and are concentrated in 
regions called CpG islands (CGI) (Jones, 2012; Illingworth & Bird, 2009). Although 
the criteria for CGIs have been subject to some debate, one common definition is a 
region of at least 200 bp, with at least 50% GC content and 60% of the expected CpG 
frequency (Gardiner-Garden & Frommer, 1987).  
 
Whereas the bulk of CpGs are methylated in vertebrates, corresponding to 
approximately 1% methylation of the genome (Ehrlich et al, 1982; Bird & Taggart, 
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1980), CpG islands are generally unmethylated (Illingworth & Bird, 2009). 
Hypomethylation of CGI regions in germline cells explains why these regions have 
been protected against CpG depletion by deamination mutations (Jones, 2012).  
 
60-70% of mammalian promoters are associated with CGIs, accounting for half of the 
CGIs in the genome (Illingworth & Bird, 2009; Illingworth et al, 2010). Genes with 
CGI promoters are predominantly housekeeping genes although some are tissue-
specific or development regulatory genes (Deaton & Bird, 2011). Promoter or 
transcription start site (TSS) methylation is strongly associated with transcriptional 
repression but CGI promoters can be silent without being methylated (Weber et al, 
2007; Deaton & Bird, 2011). Methylation of CGI promoters generally reflects long 
term and stable repression, for example of pluripotency genes in somatic cells (Mohn et 
al, 2008). While inhibiting transcription initiation, DNA methylation does not appear to 
block elongation as gene bodies are often significantly methylated (Laurent et al, 2010; 
Jones, 2012). Interestingly, gene body methylation is not uniform, but higher in exons 
than introns, which has inspired theories concerning regulation of splicing (Laurent et 
al, 2010; Jones, 2012). 
 
In addition to transcriptional regulation, DNA methylation is also highly important for 
genome stability by silencing transposable elements, stabilizing repetitive sequences, 
X-chromosome inactivation and parental gene imprinting (Jones, 2012). 
 
1.5.1 DNA methylation writers, DNMTs 
DNA methylation is performed by DNA methyltransferases, of which there are three 
catalytically active members in mammals: DNMT3A, DNMT3B and DNMT1 (Moore 
et al, 2012). These enzymes transfer a methyl group from SAM to the C5 position 
carbon of cytosine (Moore et al, 2012). DNMT3A and DNMT3B are de novo enzymes 
active on previously unmethylated DNA (Okano et al, 1998; 1999), whereas DNMT1 
is a maintenance enzyme, preferentially acting on hemimethylated DNA after 
replication to conserve methylation patterns (Pradhan et al, 1999). All three enzymes 
are required for proper development. Dnmt1 and Dnmt3b knockouts are embryonically 
lethal in mice, whereas Dnmt3a knockout mice die a few weeks after birth (Okano et 
al, 1999; Li et al, 1992). Both DNMT3A and B are required for establishing 
methylation patterns during development (Jones, 2012; Okano et al, 1999), and 
although highly similar they have separate functions and expression patterns (Xie et al, 
1999). While DNMT3B is preferentially expressed in stem cells and low in most 
differentiated tissues, DNMT3A and DNMT1 are relatively ubiquitously expressed 
(Xie et al, 1999; Yen et al, 1992). 
 
DNMT1 localizes to the replication fork during S-phase and targets hemimethylated 
DNA through its accessory factor UHRF1 (Leonhardt et al, 1992; Bostick et al, 2007). 
DNMT3A and DNMT3B interact with DNMT3L, a non-catalytic DNMT family 
member that stimulates DNMT3A/B activity (Hata et al, 2002; Chen et al, 2005). 
DNMT3L is necessary for establishing methylation patterns in early development 
(Hata et al, 2002; Chen et al, 2005; Moore et al, 2012), but is not expressed in most 
adult tissues, except for in germ cells and thymus (Hata et al, 2002; Aapola et al, 
2000). 
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1.5.2 Effects of DNA methylation, 5mC readers 
The mechanisms behind DNA methylation effects on chromatin and transcription have 
not been completely elucidated. Broadly speaking, however, they can be classified into 
two categories; attraction of specific 5mC binding proteins and blocking binding of 
5mC sensitive proteins (Klose & Bird, 2006). 
 
Members of three protein families have been shown to bind 5mC: the methyl-CpG-
binding domain (MBD) family, the zinc-finger (ZF) family and the SRA-family, 
including the DNMT1 associated factor UHRF1 and the related UHRF2 (Buck-
Koehntop & Defossez, 2013). Of the MBD family, MECP2, MBD1, MBD2 and 
MBD4 have been shown to bind methylated DNA in different sequence contexts. 
MBD1, MBD2 and MECP2 have described functions in gene repression (Hendrich & 
Bird, 1998; Lewis et al, 1992; Cross et al, 1997; Buck-Koehntop & Defossez, 2013). 
Notably, this effect appears to be, at least in part, mediated through recruitment of other 
chromatin modifiers (Klose & Bird, 2006). For example both MBD2 and MECP2 are 
involved in targeting corepressors such as HDAC-containing complexes to methylated 
DNA (Ng et al, 1999; Jones et al, 1998) and MBD1 interacts with the H3K9 
methyltransferae SETDB1 (KMT1E) (Sarraf & Stancheva, 2004). 
 
DNA methylation also can block or decrease binding of proteins to DNA, including 
transcription factors such as MYC (Jones, 2012; Klose & Bird, 2006). Comparably, 
proteins harboring a ZF-CXXC domain have been shown to preferentially bind 
unmethylated DNA (Long et al, 2013). ZF-CXXC-containing proteins include the 
H3K36me demethylases KDM2A and KDM2B, CFP1 (which interacts with the 
SETD1 H3K4 methylase complex), and the H3K4 KMTs MLL and MLL2 (Long et al, 
2013). 
 
1.5.3 DNA methylation erasers  
There are two conceivable mechanisms by which DNA can be demethylated: passive 
and active demethylation. Passive demethylation simply entails lack of remethylation 
of the daughter strand of newly synthesised DNA. Active demethylation is more 
controversial, but several putative demethylases have been proposed (Bhutani et al, 
2011; Schomacher, 2013). Despite the on-going discussion concerning putative 
demethylases it is clear that active DNA demethylation does occur as postmitotic or 
non-dividing cells have been shown to loose DNA methylation at specific loci upon 
differentiation or gene induction (Bruniquel & Schwartz, 2003; Klug et al, 2010; 
Miller & Sweatt, 2008). In addition, active demethylation on a global scale has been 
observed in the paternal genome after fertilization, but before cell division, as well as in 
germ line progenitors (Mayer et al, 2000; Schomacher, 2013). 
 
To date, several pathways of DNA demethylation have been proposed with varying 
amounts of evidence and counter-evidence. In plants, a 5mC-specific glycosylase has 
been shown to mediate DNA demethylation together with the base excision repair 
(BER) machinery, but to date no such mechanism has been confirmed in mammals 
(Schomacher, 2013). However, most of the proposed pathways involve DNA repair 
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mechanisms, epecially BER or nucleotide excision repair (NER), excising the 5mC or 
modified 5mC base (Franchini et al, 2012). 
 
In one proposed DNA demethylation pathway, the DNA-deaminase AID has been 
suggested to deaminate modified cytosines, leading to their removal by BER pathways 
(Franchini et al, 2012). The GADD45 proteins are other examples of proposed 
mediators of DNA demethylation. These proteins have been suggested to direct the 
DNA repair machinery for removal of 5mC at specific loci, although the theory has 
been questioned due to inconclusive results (Kohli & Zhang, 2013; Schomacher, 
2013). 
 
The Ten-eleven translocation (TET) enzymes, first identified by the occurrence of the 
TET1-MLL fusion gene in acute myeloid leukemia (AML) (Ono et al, 2002), have been 
strongly implicated in DNA demethylation (Pastor et al, 2013), and are the most 
accepted candidates for mediators of active DNA demethylation. There are three 
members of this family, TET1, TET2 and TET3, with different expression patterns in 
different tissues (Guibert & Weber, 2013). TET enzymes oxidize 5mC in a series of 
steps to hydroxymethyl- (5hmC), formyl- (5fC) and finally carboxylcytosine (5caC) 
(Tahiliani et al, 2009; Ito et al, 2010; 2011). The modified 5mC may be diluted by 
replication, as DNMT1 is not active on hemi-hydroxymethylated DNA (Hashimoto et 
al, 2012). Alternatively, it could be removed by the BER machinery where the DNA 
glycosylase TDG excises 5fC or 5caC thereby causing demethylation (Kohli & Zhang, 
2013). There is ample evidence supporting the function of TET enymes in DNA 
demethylation. For example, TET3 is required for the demethylation of the male 
pronucleus and the decrease of 5mC is associated with an increase of 5hmC, suggesting 
demethylation through hydroxylation (Wossidlo et al, 2011). 
 
1.5.4 DNA hydroxymethylation 
The discovery of the TET enzymes and their activity raised the possibility that the 
products of 5mC oxidation may be more than demethylation intermediates, and have 
distinct epigenetic roles. 5hmC in particular, has received attention in this capacity 
(Guibert & Weber, 2013). 5hmC has been detected in numerous tissues and is 
especially high in ESCs and brain (Tahiliani et al, 2009; Kriaucionis & Heintz, 2009; 
Guibert & Weber, 2013). Importantly it is far more abundant than 5fC and 5caC 
(Pastor et al, 2013). Studies show slightly different genome-wide distributions of 
5hmC depending of the cell type examined. Studies in murine and human ESC and 
brain cells show that this modification is found at promoters, in gene bodies and cis-
regulatory elements such as enhancers (see section 1.7.3), whereas other cell types 
appear to have 5hmC depletion in promoters (Shen & Zhang, 2013; Pastor et al, 2013). 
In ESC, differentiation induced enhancer activation is associated with increases in 
5hmC levels (Serandour et al, 2012). However, more work must be perfomed to 
completely resolve whether 5hmC has a function of its own, rather than as a DNA 
demethylation intermediate. Interestingly, although not recognized by most MBD 
family members, one study indicates that 5hmC might be specifically bound by MBD3, 
which has a low affinity for 5mC (Yildirim et al, 2011). 
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1.6 CROSSTALK BETWEEN CHROMATIN MODIFIERS 
As already touched upon, there is extensive crosstalk between different chromatin 
modifications. This is best illustrated by the presence of multiple chromatin 
modification activities in the same complexes, and by the role of chromatin 
modifications in recruiting these complexes. One excellent example is the NuRD 
complex that contains HDAC1 and 2 as well as the chromatin remodeler CHD3 or 
CHD4 (Allen et al, 2013). The complex also contains MBD2 or MBD3, enabling 
targeting to methylated DNA regions. In addition, methylation of H3K9 enhances 
binding to chromatin by the PHD (plant homeo domain) domains of CHD4, whereas 
H3K4 methylation reduces it (Musselman et al, 2012). Thus, a single chromatin-
modifying complex is affected by histone modifications and DNA methylation, and 
will itself modify histones and rearrange nucleosomes.   
 
The best characterized crosstalk between DNA methylation and histone modifications 
concerns methylation of H3K4 and H3K9. DNMT3A and DNMT3B, as well as 
DNMT3L, have ADD-domains (ATRX-Dnmt3-Dnmt3L) that bind to histone H3 and 
this interaction is abolished by H3K4 methylation (Ooi et al, 2007; Otani et al, 2009; 
Zhang et al, 2010). In addition, several histone methyltransferases, including the H3K4 
KMTs MLL and MLL2, have a CXXC domain specific for unmethylated DNA (Long 
et al, 2013). Similarly, several H3K9 KMTs interact with and recruit DNMTs, whereas 
MBD1 interacts with the two H3K9 KMTs SUV39H1 (KMT1A) and SETDB1 
(KMT1E), demonstrating another two-way communication between histone 
modifications and DNA methylation (Hashimoto et al, 2010). It is clear that chromatin 
modifications exist and act in networks of interdependent mechanisms, the complexity 
of which we still have a lot to learn about. 
 
1.7 TRANSCRIPTION 
1.7.1 Basic transcription machinery 
RNA polymerase II (pol II) transcribes protein coding genes as well as many functional 
RNA genes. Transcription regulation is required to ensure expression of the correct 
genes for a given cell type. Pol II transcription can be divided into three phases: 
initiation, elongation and termination. The minimal machinery required for 
transcription initiation consists of the pol II complex and five general transcription 
factors (GTFs) (TFIIB, - D, -E, -F and –H) (Liu et al, 2013). The GTFs and pol II bind 
sequentially to the core promoter of genes, starting with TFIID, to form the 
preinitiation complex (PIC). TFIIH unwinds the DNA helix at the transcription start 
site (TSS) to allow access of pol II to single stranded DNA in order to start RNA 
synthesis (Smolle & Workman, 2013). TFIIH phosphorylates ser5 of the C-terminal 
domain (CTD) of RBP1, the largest subunit of pol II, as pol II escapes the promoter. At 
this point pol II dissociates from the GTFs and enters into early elongation after which 
it acquires CTD ser2 phosphorylation (Smolle & Workman, 2013; Liu et al, 2013). 
The phosphorylated CTD recruits factors for efficient elongation, termination and 
mRNA processing. The RNA receives a 7-methylguanosyl cap in early elongation, and 
is polyadenylated at the 3’ end as transcription is terminated. 
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The core promoter is a minimal set of regulatory DNA-elements required for directing 
pol II transcription, often containing a TATA-box, and is located immediately upstream 
of the TSS (Butler & Kadonaga, 2002). However, pol II transcribed genes are 
associated with multiple regulatory DNA elements in addition to the core promoter. 
These cis-regulatory DNA sequences include the proximal promoter and enhancers, 
which contain binding sites for specific transcription factors (Butler & Kadonaga, 
2002). While only the PIC is required for basal transcription, initiation can be greatly 
enhanced or repressed by the binding of specific transcription factors.  Normally 
transcriptional activators bind to regulatory DNA-sequences and recruit co-activators 
and the transcriptional machinery, leading to formation of the PIC (Weake & 
Workman, 2010).  
  
 
1.7.2 Epigenetics and transcription 
Chromatin has a major influence on transcription by for example affecting regulation of 
initiation, posing as an obstacle to elongation and preventing cryptic transcription.  
As mentioned in the previous section, transcriptional activators initiate gene induction 
by binding to regulatory sites and recruiting coactivator complexes that act on 
chromatin, including histone-modifying enzymes such as KATs and CRCs. These 
enzymes contribute to an accessible chromatin format facilitating initiation, but also to 
recruitment of further effector proteins recognizing histone modifications (Weake & 
Workman, 2010; Smolle & Workman, 2013). Correspondingly, repressors recruit 
chromatin modifiers such as HDACs and CRCs, leading to a closed and less permissive 
chromatin conformation, negatively affecting transcription.  
 
Elongation requires the polymerase to negotiate nucleosomal DNA. This is 
accomplished through the activities of CRCs and histone chaperones proteins. CRCs 
evict and remodel nucleosomes in front of the elongating polymerase, and reassemble 
nucleosomes in its wake with the help of histone chaperones that accept the evicted 
histones and escort them to reassembly (Clapier & Cairns, 2009). This is not only 
important for efficient elongation, but also to prevent transcription from cryptic start 
sites behind pol II (Li et al, 2007; Pointner et al, 2012).  
 
Histone modification patterns are dramatically different in promoters and in bodies of 
transcribed genes. For example, while histone acetylation is highest in the promoter 
regions of active genes, H3K36me3 is enriched in the body of transcribed genes 
(Smolle & Workman, 2013; Barski et al, 2007). Studies in yeast have shown that the 
H3K36 KMT Set2p is recruited to transcribed genes by association with the 
phosphorylated CTD of pol II and H3K36 methylation prevents cryptic transcription by 
recruitment of CRCs and HDACs (Carrozza et al, 2005; Smolle & Workman, 2013). 
 
1.7.3 Enhancers 
Enhancers are cis-regulatory elements that can positively regulate transcription from a 
cognate promoter over substantial genomic distances of up to thousands of kilobases 
(Calo & Wysocka, 2013). Enhancers are approximately 200-500 bp long and contain 
clusters of recognition sequences for DNA-binding proteins and thereby act as binding 
  13 
platforms for transcription factors (Calo & Wysocka, 2013). They are believed to favor 
transcription through DNA-looping, bringing enhancer and target promoter into close 
proximity and allowing contact between the proximal promoter and enhancer-bound 
transcription factors as well as delivery of accessory factors needed for transcription 
(Calo & Wysocka, 2013; Smallwood & Ren, 2013). Studies and estimates suggest that 
genes are often regulated by multiple enhancers. As different combinations of 
transcription factors may bind different enhancers this would allow for complex 
transcription patterns. Correspondingly genes that need to be coordinately activated 
under certain circumstances may share similar enhancers. This confers an additional 
layer of control and flexibility to transcriptional regulation (Cho, 2012).  
 
A major breakthrough in studying enhancer biology was the realization that these 
regions are associated with certain chromatin features. Among these, the most well 
known are the presence of DNA hypersensitive sites, binding of the KAT p300 
(KAT3B) and the CRC ATPase SMARCA4 as well as enrichment of H3K4me1 but 
lack of H3K4me3 (Thurman et al, 2012; Heintzman et al, 2007; Rada-Iglesias et al, 
2011). In addition, epigenetic marks can be used to separate active from inactive 
enhancers. Active enhancers are associated with H3K27ac while enhancers that are in a 
poised state may have H3K27me3 (Creyghton et al, 2010; Rada-Iglesias et al, 2011).  
 
The discovery of enhancer chromatin signatures inspired whole genome experiments 
aiming to identify enhancers based on these characteristics. The ENCODE project 
identified 400.000 putative enhancers, with current estimates predicting the real number 
to be around one million (The ENCODE Project Consortium, 2012; Smallwood & 
Ren, 2013). Although the functionality of most of these sites remains to be tested, 
experiments support the predictive power of epigenetic features to identify enhancers 
(May et al, 2012; Visel et al, 2009; Calo & Wysocka, 2013).   
 
In 2013 several studies reported the finding of “super-enhancers”; clusters of multiple 
enhancers bound by high levels of mediator and master transcription factors (Whyte et 
al, 2013; Lovén et al, 2013; Hnisz et al, 2013). Super-enhancers are generally 
associated with genes for cell type specific transcription factors or other factors with 
cell type specific functions and are therefore likely involved in regulation of cell fate. 
 
1.8 HEMATOPOIESIS: LINEAGES AND CELLS 
Hematopoiesis is the process by which all blood cells develop from a common 
hematopoietic stem cell (HSC) pool (figure 2). The descendants of the multipotent HSC 
pass through increasing degrees of restriction, finally giving rise to thrombocytes, 
erythrocytes and white blood cells of both the innate and the acquired immunesystem 
(Orkin, 2000). Postnatal hematopoiesis is located in the bone marrow. HSCs are rare 
and divide infrequently, but because of the high proliferation rates in later stages of 
blood development a HSC is capable of producing 1*106 mature cells after only 20 
rounds of proliferation (Hoffbrand & Moss, 2011). Approximately 1*1010 blood cells 
are formed each day, with potential for increased production if needed (Hoffbrand & 
Moss, 2011) Differentiation proceeds from the HSC to the lineage committed common 
myeloid progenitor (CMP) or common lymphoid progenitor (CLP) (Orkin, 2000). 
Further lymphoid development gives rise to T cells, B cells and NK-cells, whereas the 
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myeloid lineage includes the mast cells, monocyte/macrophages and granulocytes such 
as neutrophils, basophils and eosinophils. The megakaryocyte-erythrocyte progenitor 
(MEP), from which erythrocytes and thrombocytes develop, also stem from CMP 
(Iwasaki & Akashi, 2007). Dendritic cells, on the other hand, can have either myeloid 
or lymphoid origin.  
 
 
 
Figure 2 Hematopoeisis  
Schematic illustration of hematopoietic development and mature blood cell types. All blood cells descend 
from a common hematopoietic stem cell (HSC) and differentiation progresses through stages of 
increasing restriction. The common myeloid progenitor (CMP) gives rise to cells of the myeloid lineage, 
whereas the lymphoid cells develop from the common lymphoid progenitor (CLP). The 
granulocyte/macrophage progenitor (GMP) is bipotent and develops into monocytes or neutrophils. 
Several intermediary cell stages and progenitors have been omitted for clarity. 
 
 
Lineage choice may depend on chance or external signals in the form of growth factors. 
These are mainly produced by bone marrow stromal cells and stimulate self renewal 
and multipotency of stem cells, as well as proliferation and differentiation. The signal is 
transmitted into the nucleus and the transcriptional program by transcription factors, the 
combination and levels of which control the differentiation process. For example, the 
transcription factor GATA-2 regulates HSC survival (Tsai & Orkin, 1997), PU.1 and 
the C/EBP family are involved in myeloid commitment (Iwasaki & Akashi, 2007) 
whereas GATA-1 is required for erythroid and megakaryocytic development (Orkin et 
al, 1998; Fujiwara et al, 1996) and IKAROS (IKF1) is essential for lymphoid 
differentiation (Wang et al, 1996a) although many of these are important for multiple 
lineages. 
 
Hematopoietic cell populations can be distinguished and purified based on the 
expression of surface proteins. A wide range of well characterized surface markers 
have been described allowing isolation of quite specific cell types. For example, HSCs 
CMP CLP
HSC
GMP
Megakaryocyte
Macrophage
Myeloid 
dendritic cell
Monocyte Neutrophil Basophil Eosinophil
T cell B cell
Plasma cell
Natural 
killer cell
Lymphoid 
dendritic cell
Erythrocyte Mast
cell
Thrombocytes
  15 
and early progenitors, but not more mature cell types, express CD34. As the HSC 
develop into CMP or CLP progenitor cells, they start expressing CD38 in addition to 
CD34, whereas HSCs are CD38 negative.   
 
1.8.1 Granulopoiesis and neutrophils 
The white blood cells of the myeloid lineage, i.e. monocytes and the granulocytes 
(neutrophils, eosinophils and basophils) are phagocytes. As parts of the innate immune 
system these cells constitute our first line of defence against pathogens. Of the 
granulocytes, the neutrophils are by far the most abundant with blood counts reaching 
1*1010 cells/L (60-70% of leukocytes in blood), and a production rate of 1-2*1011 per 
day in an adult human (Hoffbrand & Moss, 2011; Borregaard, 2010). The cytoplasm 
of the mature neutrophil contains granules and the nucleus is characteristically 
polymorphic with two or more lobes.  
 
 
 
Figure 3 Overview of granulopoiesis 
Among the first differentiation stages after granulocytic commitment is the highly proliferative 
myeloblast. The characteristic granules start forming in the promyelocyte stage and cells seize 
proliferation as myelocytes. Late granulopoiesis is accompanied by changes in nuclear morphology to the 
trade-mark multilobed shape in mature bone marrow neutrophils. 
 
 
Neutrophil differentiation is regulated by several transcription factors at different 
stages. For example, granulocytes and monocytes develop from a common progenitor 
(GMP). The differentiation choice after this stage involves the balance of transcription 
factors C/EBPα and PU.1, both required for granulopoiesis (Iwasaki & Akashi, 2007). 
High PU.1 expression pushes cells toward monocytic differentiation whereas C/EBPα 
and somewhat lower PU.1 levels promote granulocyte development (Mak et al, 2011). 
The repressor GFI-1 is also required for granulopoiesis and is involved in the same 
transcriptional network (Karsunky et al, 2002).  
 
Cellular maturation progresses through a series of cell stages, where the early and 
intermediate stages are highly proliferative until the myelocyte stage, after which the 
precursor cells are postmitotic (figure 3). There is a large cache of neutrophils in the 
bone marrow, but after release into the blood stream the cells circulate for only 6-10 
hours before migration out into the surrounding tissues, where they normally survive 4-
5 days (Hoffbrand & Moss, 2011). Granule synthesis begins at the promyelocyte stage 
and continues throughout differentiation (Borregaard, 2010). The granules act as stores 
of adhesion molecules, antimicrobial peptides, proteolytic enzymes and other defensive 
factors. There are several different types of granules with specific function, formed 
sequentially during differentiation and distinguished by the presence of distinct 
components (Gullberg et al, 1997). 
Myeloblast Promyelocyte Myelocyte Meta-
myelocyte 
Band cell Neutrophil GMP
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Neutrophils converge on sites of inflammation by chemotaxis and internalize microbes 
by phagocytosis. The microbes are subsequently killed by fusion of the phagosome 
with proteolytic granules and production of reactive oxygen species. Granules can also 
be released into the extracellular environment to combat pathogens. In addition, 
neutrophils produce chemokines that aid in attracting more immune cells to the site of 
inflammation (Borregaard, 2010; Mocsai, 2013). The important role of neutrophils in 
inflammation and defence against microorganisms is illustrated by the severe effects of 
neutrophil deficiencies. Neutropenia is associated with recurrent infections that may 
become life threatening without treatment (Lakshman & Finn, 2001).   
 
1.9 EPIGENETIC MECHANISMS IN HEMATOPOIESIS 
Epigenetic mechanisms and chromatin modifications have proven to be highly 
important in development and control of differentiation. In fact, epigenetic states have 
been proposed to both stabilize cellular identity as well as drive differentiation. To 
emphasize the importance of this regulation in normal development, abnormal 
epigenetic patterns have been associated with a number of malignancies. This section 
will provide an overview of the role of chromatin modifications in normal 
hematopoiesis, and also discuss how epigenetic deregulation contributes to 
hematopoietic malignancies. 
 
1.9.1 DNA methylation in hematopoiesis 
1.9.1.1 DNMTs in hematopoiesis 
While DNA methylation was long considered to be a relatively fixed and static 
chromatin mark after embryonic development, it has in recent years been found to be 
surprisingly plastic even in adult differentiation (Meissner et al, 2008). Both DNMT3A 
and DNMT1 have been shown to have vital, but very different, roles in hematopoiesis, 
while the role of DNMT3B has been less investigated (Bröske et al, 2009; Challen et 
al, 2012; Trowbridge et al, 2009). Experiments using a mouse model with a tissue 
specific cre-lox knockout system of Dnmt3a in hematopoietic cells, demonstrated that 
DNMT3A is necessary for differentiation of HSC, but not for lineage choice (Challen 
et al, 2012). Upon reimplantation of DNMT3A-/- HSC into irradiated recipients, there 
was an accumulation of HSC. The effect was caused by reduced differentiation 
potential, supported by the observation that stem cell maintenance genes were 
upregulated while lineage differentiation genes were downregulted. However, when 
differentiation proceeded, no significant effect was observed on lineage choice, except 
for a slight skewing to B cell differentiation.  
 
In contrast, DNMT1 is required for maintenance of HSC and highly important for 
lineage specification (Bröske et al, 2009; Trowbridge et al, 2009). One study observed 
rapid death of mice due to bone marrow failure after conditional knockout of Dnmt1 in 
hematopoietic cells (Bröske et al, 2009). By instead using an inducible hypomorphic 
Dnmt1 system in a repopulation assay, it could be concluded that HSC with 
hypomorphic Dnmt1 had reduced self-renewal capacity likely due to the 
downregulation of stem cell maintenance genes. There was also a marked skewing of 
differentiation toward the myeloid lineage, whereas lymphoid commitment and B cell 
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development was blocked. Similarly, myeloerythroid transcription factors were 
upregulated in Dnmt1 hypomorphic mice, whereas lymphoid regulators were 
downregulated. These results clearly indicate that DNMT1, and maintenance of 
methylation, is important for lineage choice.  
 
Interestingly, the Dnmt1 hypomorphic mice were protected against induction of 
myeloid leukemia using the oncogenic Mll-AF9 fusion gene, possibly due to the lack of 
self-renewal capability and forced myeloid differentiation. This could also provide the 
reason behind the successful treatment of myeloid malignancies with the DNA 
methylation inhibitor 5-aza-cytidine (Kaminskas, 2005). Indeed, 5-aza-cytidine 
treatment of HSC gave similar results as Dnmt1 hypomorphic mutation (Bröske et al, 
2009), and the related inhibitor 5-aza-2’deoxycytidine causes increased numbers of 
myeloid progenitors at the expense of lymphoid progenitors (Ji et al, 2010). 
 
1.9.1.2 Genome-wide methylation changes in hematopoiesis 
In agreement with the observation that maintained methylation is required for 
lymphoid, but not for myeloid commitment, several studies have described loss of 
methylation in myeloid and erythroid cells during differentiation (Hogart et al, 2012; 
Shearstone et al, 2011; Bock et al, 2012; Ji et al, 2010; Hodges et al, 2011; Bocker et 
al, 2011). By contrast, lymphoid cells appear to show a net gain in methylation. For 
example, out of neutrophils, B cells and HSCs, neutrophils have the highest number of 
hypermethylated regions, while B cells have the fewest (Hodges et al, 2011). 
Importantly, this difference is already evident in the committed progenitors, as CLP has 
more sites of increased methylation than CMP (Bock et al, 2012).  
 
In line with the suggested regulatory role of DNA methylation in lineage specification, 
methylation changes are often associated with genes important for hematopoietic 
control, such as transcription factors, and genes involved in functions of the mature 
cells (Ji et al, 2010; Hodges et al, 2011; Bock et al, 2012; Bocker et al, 2011). The 
cell specific genes become unmethylated in the appropriate lineage and methylated in 
other cells. Methylation changes have also been described in binding sites for 
hematopoietic transcription factors and putative enhancers (Hodges et al, 2011; Lee et 
al, 2012; Bock et al, 2012; Schmidl et al, 2009; Deaton et al, 2011). In addition, 
myeloid transcription factors and their binding sites are specifically methylated in 
lymphoid cells. These observations support a role for cell type specific DNA 
methylation both in lineage specification and in safeguarding against activation of a 
myeloid transcription program in the lymphoid lineage. Interestingly, one study 
reported that differentially methylated regions (DMRs) between mature myeloid 
(neutrophils) and lymphoid (B cells) cells displayed intermediate methylation levels in 
earlier stem/progenitor cells, possibly in preparation for either outcome (Hodges et al, 
2011).  
 
It should be noted that two studies, one performed on material from human fetal bone 
marrow on B cell development and one comparing CD34+ progenitor cells with T 
cells, reported that lymphoid commitment is associated with general demethylation in 
contrast to the increased methylation reported in other studies (Lee et al, 2012; 
Schmidl et al, 2009). The reason for this discrepancy is unclear, but could be caused by 
methodological differences. 
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In addition to early lineage choices, DNA methylation also appears to be involved in 
later hematopoietic development as even closely related cell types, such as human 
conventional and regulatory T cells, display regions of differential methylation 
(Schmidl et al, 2009). Again, DMRs were associated with cell type specific genes and 
commonly located in promoter distal sites with methylation sensitive enhancer activity. 
Methylation changes are generally smaller between more differentiated cell types than 
earlier in development, and differ more between distant tissues (Deaton et al, 2011; 
Lee et al, 2012; Bock et al, 2012; Bocker et al, 2011).  
 
Studies comparing samples from individuals of different ages indicate a predominant 
DNA hypomethylation effect of ageing in both human HSC (Bocker et al, 2011) and T 
cells (Heyn et al, 2012). The T cell study found that the hypomethylated genes were 
enriched for genes that are differentially expressed in ageing HSC. The genes found to 
be hypomethylated as a consequence of age in HSC, on the other hand, overlapped 
significantly with myeloid specific genes that are demethylated during myelopoiesis. 
Intriguingly, age is also associated with skewing of hematopoiesis toward the myeloid 
lineage (Pang et al, 2011). 
 
Although DNA methylation studies have historically been focused on CGIs in 
promoters, several of the studies mentioned above, as well as studies in other tissues, 
report that the majority of methylation changes in normal development occur outside of 
CGIs (Ji et al, 2010; Lee et al, 2012; Irizarry et al, 2009; Hogart et al, 2012). Data 
suggests that changes are particularly common in CGI-adjacent regions, called shores, 
and that these changes may be better correlated with changes in expression than 
changes in the CGIs themselves (Ji et al, 2010; Irizarry et al, 2009). Interestingly many 
cell type specific differentially methylated sites (DMSs), including differences in CGIs, 
are not in immediate proximity to the promoter or TSS, but instead located in promoter 
distal elements, as already mentioned, or in gene bodies (Lee et al, 2012; Hodges et al, 
2011; Schmidl et al, 2009; Deaton et al, 2011). 
 
1.9.2 Histone modifications in hematopoiesis 
Several studies have shown that, like DNA methylation, histone modifications may be 
involved in regulating plasticity and differentiation. Bivalent domains (see section 
1.3.2) appear to participate in regulating genes related to hematopoietic control. Many 
HSC and progenitor-specific genes are associated with bivalent domains already in 
ESCs but lose the repressive H3K27me3 in early blood cells (Adli et al, 2010; 
Abraham et al, 2013). Later in differentiation they become associated with K27me3 
and silenced again (Abraham et al, 2013). Notably, many of these genes have 
important roles in differentiation including critical transcription factors (Abraham et al, 
2013; Adli et al, 2010). In HSCs bivalent domains are present at lineage specifying 
genes. Strikingly, the level of H3K4me3 at HSC bivalent promoters reflects the number 
of differentiated cells the gene will be transcribed in and is accordingly high at master 
regulators of blood lineages (Adli et al, 2010). 
 
In general HSC and multipotent progenitors have a more permissive chromatin state, 
allowing access to genes of multiple lineages. In line with this, hematopoietic 
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commitment is preceded by low or background transcription of genes belonging to 
several lineages (Hu et al, 1997; Miyamoto et al, 2002). 
 
Comparison of global H3 and H4 acetylation levels in CD34+ cells vs. CD34- cells 
indicates that HSC and progenitor cells have higher levels of acetylation than 
committed cells (Chung et al, 2009). In addition, acetylation turnover was higher in 
more immature cells indicting more dynamic and open chromatin. In general, more 
promoters are associated with bivalent or active marks in HSCs than in committed or 
differentiated blood cells (Cui et al, 2009; Weishaupt et al, 2010; Abraham et al, 
2013). In accordance with bivalent genes being poised for transcription in later 
development, active and bivalent chromatin marks in HSC have been detected at 
promoters of lineage specific genes, despite the genes being silent or lowly expressed 
(Maes et al, 2008; Orford et al, 2008; Weishaupt et al, 2010; Abraham et al, 2013; 
Hattangadi et al, 2011). Interestingly, bivalent marks of cell specific genes may persist 
in closely related cell types, although they are lost in distant cell types, possibly 
indicating some residual plasticity (Abraham et al, 2013). 
 
A study on umbilical cord blood focusing on a panel of 20 lymphoid and 
myeloerythroid genes reported that HSCs had a broader acetylation profile with genes 
of multiple lineages acetylated, whereas lineage committed cells only displayed 
acetylation at genes appropriate for that lineage (Maes et al, 2008). Interestingly 
several lymphoid genes showed H3K4me2 in HSCs, and during B cell development 
H3K4me2 was replaced by H3K4me3 at B cell specific genes while methylation was 
lost at these genes in T cells. The authors suggested that H3K4me2 may be an 
additional indicator of a poised state. A similar observation was made in murine 
erythroid differentiation where a group of silent promoters in HSC were characterized 
by H3K4me2, but absence of H3K4me3 (Orford et al, 2008). This subset was enriched 
for lineage specific genes and upon erythroid differentiation, non-erythroid genes lost 
H3K4me2, while genes that gained H3K4me3 showed increased expression. The 
authors concluded that the wider H3K4me2 profile of HSCs reflected the 
differentiation potential.  
 
Collectively, available data demonstrates that genes relevant to hematopoietic 
differentiation or function of the mature blood cell types are associated with bivalent or 
permissive chromatin states in HSCs and progenitor cells, priming them for expression. 
Therefore, the chromatin state of hematopoietic genes can be said to define the 
plasticity of HSCs. 
 
1.9.3 Chromatin modifying factors in hematopoiesis 
As expected from the global changes of epigenetic marks in blood cell differentiation, 
many individual chromatin regulators have been shown to have important roles in 
hematopoiesis. In addition to the requirement for DNMT3A and DNMT1 in 
hematopoiesis (discussed in section 1.9.1.1), the putative DNA demethylase TET2 is 
also required for normal blood development. TET2 and TET3 are both expressed in 
peripheral blood, whereas TET2 is the only TET enzyme in bone marrow (Lorsbach et 
al, 2003). TET2 deficient mice show an expansion of the HSC population with 
decreased differentiation potential that favor monocytic development (Butler & Dent, 
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2013). The TET2 deficient mice also develop leukemia at an early age (Butler & Dent, 
2013). 
 
Several histone modifying enzymes, or subunits of histone modifying complexes, have 
been demonstrated to be important for hematopoiesis. For example, the KAT MOZ 
(KAT6A) is required for maintenance of the HSC and progenitor pool, but not for 
differentiation (Thomas, 2006), and overexpression of HDAC1 inhibits myeloid 
differentiation (Wada et al, 2009). 
 
The H3K4 methyltransferase MLL is highly relevant in the hematopoietic system as 
indicated by its frequent involvement in hematological malignancies (discussed in 
section 1.9.4.1) (Chung et al, 2012). MLL is required for HSC self-renewal, and mice 
with induced Mll deletion in the bone marrow die after three weeks from bone marrow 
failure and HSC depletion (Jude et al, 2007). In contrast, committed progenitors do not 
require MLL (Jude et al, 2007).    
 
Several PcG factors of both PRC1 and PRC2 (see section 1.3.2) are known to have 
roles in normal hematopoiesis. BMI1, a subunit of PRC1, is important at several stages 
of blood development. BMI1 deficiency in mice causes increased B cell development 
due to premature derepression of regulators of B cell development, the promoters of 
which are normally marked with bivalent domains in HSCs (Oguro et al, 2010). Bmi1 
mutation also causes HSC depletion in mice (Park et al, 2003). Correspondingly, 
overexpression of BMI1 or the PRC2 KMT subunit EZH2 increases HSC self-renewal 
(Iwama et al, 2004; Kamminga, 2006). In addition, EZH2 overexpression also leads to 
abnormal myeloid expansion in mice (Herrera-Merchan et al, 2012), while Ezh2 
mutation causes deficiencies in early B cell development (Su et al, 2002; Mochizuki-
Kashio et al, 2011).  
 
LSD1 regulates lineage specific hematopoietic genes through its interaction with the 
repressor GFI1 (Saleque et al, 2007). Lsd1 knockdown in mice causes expansion of 
myeloerythroid progenitors by enhancing proliferation, while inhibiting terminal 
differentiation of granulocytes, megakaryocytes and erythrocytes but stimulating 
monocyte development (Sprüssel et al, 2012). 
 
Several CRCs have critical roles in blood development. Deletion of the gene encoding 
the ATPase CHD4 of the NuRD complex, generally associated with gene repressive 
functions, in bone marrow of mice causes expansion of the HSC pool and accumulation 
of erythroid progenitors (Yoshida et al, 2008). In contrast, lymphoid and other myeloid 
progenitors are reduced. CHD4 is also required for several steps of T cell development 
(Williams et al, 2004). Likewise, the BAF complex has been demonstrated to be 
essential in hematopoiesis. A recent study revealed that the BAF53a (ACTL6A) 
subunit of the BAF complex is required for HSC self-renewal and proliferation of 
myeloid progenitors. In line with this, BAF53A depletion in mice resulted in bone 
marrow failure (Krasteva et al, 2012). In addition, expression of a dominant negative 
version of SMARCA4, one of the two possible ATPase cores of BAF, causes a block in 
myeloid maturation in culture (Vradii et al, 2006). SMARCA4 is also required for 
normal T cell development (Chi et al, 2003). 
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1.9.4 Epigenetics in hematopoietic malignancies 
Approximately 7% of all cancer cases are hematopoietic malignancies. As in all 
malignancies, these are the result of accumulation of mutations that may be influenced 
by inherited and environmental factors, causing a clonal expansion of transformed 
cells. There are numerous kinds on hematological malignancies. The uncontrolled 
proliferation can occur either in the bone marrow, as with leukemias, which are 
characterized by expansion of white blood cells, or in the peripheral tissue as in 
lymphomas where the malignancy starts in the lymphoid tissue. Subdivisions further 
group malignancies according to for example the cell/lineage of origin and if it has 
acute or chronic progression. In addition, there are other proliferative diseases of the 
blood that may in time develop into malignancies. One such disease is myelodysplastic 
syndrome (MDS)  which progresses to acute myeloid leukemia (AML), the most 
common acute leukemia in adults. 
 
Perhaps the earliest evidences of the pivotal role of epigenetics in hematopoietic 
regulation came from the involvement of chromatin modifiers in blood malignancies. 
In this section some examples of the involvement of epigenetic mechanisms in 
hematopoietic malignancies will be presented, with emphasis on AML and DNA 
methylation. 
 
1.9.4.1 DNA methylation in hematopoietic malignancies 
Aberrant DNA methylation is one of the hallmarks of cancer, and typically involves 
general hypomethylation causing destabilization of the genome and local 
hypermethylation of CpG islands, causing silencing of tumor suppressor genes 
(Sandoval & Esteller, 2012). Changes in DNA methylation are recognized as 
important contributors to many hematopoietic malignancies (Cahill & Rosenquist, 
2013; Schoofs & Müller-Tidow, 2011; Issa, 2013). DNMT3A is recurrently mutated in 
AML and MDS causing reduced or abolished enzymatic activity and DNMT3A 
mutations are associated with poor prognosis (Ley et al, 2010; Walter et al, 2011; Yan 
et al, 2011). 
  
TET2 mutations are common in various myeloid malignancies (Chan & Majeti, 2013). 
Also, mice without TET2 are prone to develop hematopoietic malignancies, especially 
of the myeloid lineage (Butler & Dent, 2013). One study showed that TET2 mutations 
in patients with myeloid malignancies correlated with decreased 5hmC levels and 
increased DNA methylation (Ko et al, 2010). Gain-of-function mutations in the IDH1 
and IDH2 enzymes are also common in AML, but mutually exclusive with TET2 
mutations, and are associated with hypermethylation of leukemic cells (Figueroa et al, 
2010; Chan & Majeti, 2013). These mutations cause the enzymes to convert their 
normal product α-KG to 2-hydroxyglutarate (2-HG), which is structurally similar to α-
KG (Figueroa et al, 2010). TET2 requires α -KG as a cofactor and is inhibited by 2-
HG, accounting for the similarity between TET2 and IDH caused AMLs (Figueroa et 
al, 2010).   
 
The role of DNA demethylation related factors in myeloid malignancies is striking 
considering the decreases of DNA methylation associated with normal myeloid 
development, and how Dnmt1 mutation hampers induction of AML. It is tempting to 
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speculate that the possible DNA demethylation deficiency caused by TET2/IDH 
mutations in AML blocks differentiation and is the mechanism behind leukemic 
transformation. However, it is more difficult to reconcile the apparent oncogenic effect 
of the TET2/IDH associated demethylation deficiency with the oncogenic effect of 
DNMT3A mutations, as they should intuitively have opposite effects. Still, TET2/IDH 
and DNMT3A mutations, are not only common in the same type of leukemias, but have 
also been found in the same clones (Welch et al, 2012; Patel et al, 2012). One possible 
explanation may be some level of locus specificity that influences the final outcome. 
Indeed, although DNMT3A mutation causes no global change in DNA methylation in 
HSCs, locus specific hypomethylation was observed at genes frequently overexpressed 
in leukemias (Challen et al, 2012). Intriguingly, many of the detected DMRs showed 
increased methylation, especially in CGIs. Also, a recent study describes expansive 
regions of hypomethylation, called canyons, the borders of which are maintained by 
DNMT3A (Jeong et al, 2014). In HSC these regions were enriched for TF binding sites 
and genes deregulated in leukemia.  
 
Many studies have reported changes in DNA methylation in AML, both associated 
with and independent of the cytogenetic subtype of the patient (Schoofs & Müller-
Tidow, 2011). Several studies also find correlations between methylation profiles and 
clinical outcome (Schoofs & Müller-Tidow, 2011). However, the precise methylation 
changes described sometimes differ, possibly due to the different methodologies or 
bioinformatics analysis employed. For example, MeDIP-seq (see section 2.6) on 
leukemic cells from 12 AML patients, including different cytogenetic subtypes, found 
no net change in DNA methylation compared to normal bone marrow (Saied et al, 
2012). However, several site specific alterations were located, including at known 
leukemia-associated genes. A larger study of 344 AML patients using a microarray-
based approach showed that cytogenetic subtype was the strongest factor for 
determining the DNA methylation profile (Figueroa et al, 2010). Still, many genes 
were consistently altered in AML irrespective of cytogenetic subtype. Notably, the 
study also identified a set of 15 genes, the methylation status of which could predict 
overall survival. Similarly, a study on normal karyotype AML showed that some 
mutations, including IDH mutations, were predictors of the DNA methylation profile of 
AML cells (Deneberg et al, 2011). Interestingly this study found a correlation between 
positive clinical outcome and the degree of methylation of PcG target genes. PcG 
targets in general were hypermethylated in AML and higher methylation was 
associated with disease-free survival. 
 
An extensive study produced by The Cancer Genome Atlas carefully examined 
samples from 200 AML patients using the Infinium 450k array (see section 2.6.1) as 
well as whole genome sequencing, expression profiling by microarrays and RNA-seq 
(The Cancer Genome Atlas Research Network, 2013). A large proportion of patients 
had mutations in DNA methylation related genes or chromatin modifiers, 44% and 
30% respectively, making epigenetic genes one of the most common functional groups 
to be mutated in AML. In accordance with the results presented by Figueroa et al 
(2010), the DNA methylation patterns largely reflected the underlying genotype, and 
depending on the mutations present, both hyper- and hypomethylation phenotypes were 
observed. Importantly, changes were most common in CpG poor regions where many 
methods of DNA methylation analysis used in earlier studies lack coverage.   
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Finally, the importance of DNA methylation in myeloproliferative disorders is 
highlighted by the efficacy of treatment with drugs targeting the methylation 
machinery. In fact, the DNMT inhibitor 5-aza-cytidine has been approved by the FDA 
for treatment of MDS and some types of AML (Kaminskas, 2005). 
 
1.9.4.2 Mutations in Chromatin regulators 
In line with their proposed roles in control of normal hematopoiesis, many of the 
factors discussed in section 1.9.3 have been found to be mutated in blood malignancies.  
For example, mutations of PRC2 components have been described in several myeloid 
malignancies. Interestingly, while loss-of-function of EZH2 has been reported for 
myeloid leukemias, gain-of-function mutations have been described in lymphoid 
malignancies (Butler & Dent, 2013). This distinction is in line with the effect of Ezh2 
mutation on myeloid and lymphoid development (See section 1.9.3).  
 
HDACs are other examples of chromatin modifiers that are highly relevant in blood 
malignancies as they commonly associate with oncogenic fusion proteins to cause 
aberrant repression of genes promoting differentiation (Glozak & Seto, 2007). HDAC 
inhibitors show promising results in treatment of myeloproliferative disorders, 
especially in combination therapy with e.g. DNA methylation inhibitors (Quintás-
Cardama et al, 2011). Furthermore, early experiments with inhibitors of bromodomains 
also show encouraging results against AML and mixed lineage leukemia (MLL) cells, 
further emphasizing the role of histone acetylation in blood malignancies (Zuber et al, 
2011). 
 
1.9.4.3 Leukemic fusion proteins 
In comparison to other cancers, hematological malignancies have a high incidence of 
chromosomal translocations producing oncogenic fusion proteins. Strikingly, one 
partner of these chimeras is often an epigenetic factor. Acute leukemias with 
translocations involving the MLL gene have been called the prototypical epigenetically 
driven cancer (Neff & Armstrong, 2013). MLL translocations are found in 5-10% of 
AML cases and more than 70% of childhood acute lymphoid leukemia (ALL) cases 
(Neff & Armstrong, 2013).  The precise mechanism of transformation is not fully 
understood. MLL-fusion proteins appear to bind and upregulate inappropriate genes by 
causing aberrant H3K4me and in some cases H3K79 methylation through recruitment 
of the KMT DOT1 (Okada et al, 2005; Neff & Armstrong, 2013; Krivtsov et al, 
2008). In fact, one study indicated that DOT1 may be a promising target for future 
therapy development against MLL leukemias (Daigle et al, 2011).  
 
Many other translocations involving epigenetic regulators have been reported in blood 
malignancies, such as for example the KATs MOZ and MORF (KAT6B) fused to the 
KAT CBP (KAT3A) (Rozman et al, 2004; Panagopoulos et al, 2001) and the KMT 
NSD3 fused to the nuclear pore protein NUP98 in AML (Rosati, 2002). Even non-
epigenetic fusion proteins often employ chromatin regulators in their mode of 
transformation. Fusion proteins involving a transcription factor as one partner, such as 
PML-RARα and AML-ETO, recruit chromatin-modifying enzymes to inappropriate 
targets. For example PML-RARα, found in the majority of acute promyelocytic 
leukemia (a subtype of AML) cases, recruits HDACs to genes important for 
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differentiation, causing transcription silencing and differentiation arrest (Rice et al, 
2007).  
 
In summary, the transforming abilities and high incidence of epigenetic abnormalities 
in hematopoietic malignancies, as well as the efficacy of drugs targeting these 
pathways in the clinic, clearly state the importance of chromatin regulators in blood 
development.  
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2 METHODS 
2.1 INTRODUCTION TO MICROARRAYS 
Microarray technology represents a relatively cheap and efficient method of assessing 
the levels of thousands of specific nucleic acid sequences in a sample of DNA or RNA. 
This methodology has been adapted to a wide range of applications and makes use of 
complementary sequences, usually of DNA, immobilized on a solid surface in a 
location that is predetermined (spotted arrays) or can be assessed (bead arrays). On 
bead arrays, each bead is covered in multiple copies of the same probe, which also 
contains a sequence for identification. After application of the beads to a surface, the 
location of each bead-probe can be determined. 
 
For most applications and array platforms the query sample is labelled, usually by 
flourophores or biotin for subsequent flourophore binding, and hybridized to the array. 
Scanning produces intensity values for each spot/bead corresponding to the amount of 
the complementary sequence in the sample. Microarray analysis requires careful 
consideration of data processing, including normalization methods and quality control 
assessment, but provides large amounts of data. 	  
2.2 EXPRESSION PROFILING 
In the work included in this thesis, two genome-wide methods for expression profiling 
have been used: expression microarrays and cap analysis gene expression (CAGE). As 
discussed below these methods are highly informative and have complementary uses.  
 
2.2.1 Expression microarrays 
Expression profiling using microarrays is a widely used application of microarray 
technology. Most commonly, the purified RNA sample is reverse transcribed into 
cDNA that is labelled and hybridized to a microarray. While there are many platforms 
for this application, they usually contain one or a few probes per gene, thereby yielding 
quantitative information for full-length transcripts, but usually not about TSS. Still, 
expression arrays provide transcription rate data for most known genes at a relatively 
low cost and require less computational analysis than CAGE or RNA sequencing. 
 
2.2.2 CAGE 
In paper II and III transcriptome data generated by CAGE as part of the FANTOM 5 
consortium was used. This method is based on the purification and 5’-end sequencing 
of capped transcripts yielding information on both transcription levels and the precise 
TSS and is highly quantitative and reproducible (Kanamori-Katayama et al, 2011; 
Shiraki et al, 2003). The protocol has been adapted to work with the Helicos single 
molecule sequencer, which circumvents the need for the PCR amplification and cloning 
step of the original protocol, thus avoiding the potential sequence biases these methods 
may bring (Kanamori-Katayama et al, 2011).  
  26 
Briefly, RNA is purified and first strand synthesis is performed with random primers. 
The 5’ cap is biotinylated by initial oxidation of the diol-group of the cap structure, 
followed by addition of biotin hydrazide causing covalent linkage of biotin to the cap 
(Carninci et al, 1996). The RNA-cDNA duplexes are treated with RNaseI to remove 
RNAs with incomplete cDNAs. The RNA-cDNA hybrids are purified excluding 
oligonucleotides shorter than 100 bp before isolation of capped RNAs with streptavidin 
coated beads. The cDNA is released and receives a 3’ poly-A tail by terminal 
deoxynucleotidyl transferase. The poly-A tail binds to poly-dT primers in the Heliscope 
flow cell surface and individual cDNA molecules are sequenced.  
 
Previous cloning based CAGE protocols had a read length of 20 nt but with the Helicos 
adapted protocol the median read length has been increased to 33 nt facilitating 
accurate mapping to the genome. Reads are filtered for size (20-70 nt) and alignment 
score and normalized to tags per million (TPM). Normally, the cutoff for detection is 
set at 10 TPM corresponding to approximately 5 RNA molecules per cell. Expression 
of a gene is determined either by summing up all TPM normalized tags over the refseq 
gene or, more recently, by using relative log expression (RLE) normalized data and 
merging overlapping tags into tag clusters representing TSSs. Clusters are TPM 
transformed, assigned to genes and added up to describe that gene’s expression.  
 
For RLE normalization we use the edgeR Bioconductor package for R. The RLE 
normalization method creates a median library by taking the geometric mean for each 
gene across all libraries. A scaling factor is calculated through the relationship of each 
gene of each library to the median library. The advantage of the RLE normalization is 
that it renders libraries of different sizes comparable. Only performing a TPM 
normalization allows for example very highly expressed genes, such as hemoglobin in 
erythrocytes, to have too much influence on total tag count and skew the data set. 
  
For some genes CAGE signal can be detected within exons, a phenomenon called exon 
painting. This is likely caused by recapping of longer transcripts (Affymetrix/Cold 
Spring Harbor Laboratory ENCODE Transcriptome Project, 2009) or by second 
strand synthesis at the reverse transcription step. However, using robust tag clusters 
(containing at least 10 detected molecules with the same TSS in a library) minimizes 
the effect of exon painting on data sets. 
 
2.3 CHIP-ON-CHIP 
In paper I histone modifications of the fission yeast Schizosaccharomyces pombe were 
mapped genome-wide using chromatin immunoprecipitation coupled to microarray 
analysis (ChIP-on-chip). In ChIP, antibodies specific for the protein in question are 
used to pull down the DNA fragments the protein is binding, after which the DNA is 
isolated and analyzed to determine where in the genome the protein binds.  
 
In the protocol used for paper I, cells are fixed using formaldehyde, crosslinking DNA 
and proteins. After fixation, cells are lysed and the chromatin sheared by sonication, 
before incubation with antibodies specific for example for histone modifications. The 
antibody-chromatin complexes are isolated by binding to protein A-covered beads 
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before reversal of the crosslink and protein removal. The purified DNA can then be 
analyZed by a number of techniques, including, as in paper I, using microarrays. 	  
2.4 SCHIZOSACHAROMYCES POMBE AS A MODEL SYSTEM 
The fission yeast S. pombe is an excellent model system for epigenetic studies. It is 
easily and cheaply maintained and can with little effort be cultured in large quantities. 
S. pombe is also easy to genetically modify through homologous recombination, for 
example introducing point mutations and allowing retention of endogenous promoters 
when expressing tagged versions of proteins. S. pombe has a small, well-annotated 
genome, which facilitated the early development of genome-wide microarrays for 
chromatin and expression studies. In addition, it has human-like epigenetic features, 
such as the structure of the centromeres and heterochromatin. However it lacks for 
example DNA methylation and H3K27 methylation.  
 
2.5 BLOOD AS A MODEL FOR DIFFERENTIATION 
Understanding the mechanisms governing hematopoiesis is highly relevant to 
understanding leukaemia and other blood disorders, and for the future development of 
treatments, including regenerative medicine and cancer therapy. In addition blood 
constitutes a convenient system for studying differentiation since it is composed of 
several cell types stemming from a common HSC. Unlike most other tissues the 
different cell types can be readily purified with FACS (fluorescence-activated cell 
sorting) from bone marrow, avoiding culturing steps known to induce abnormal 
changes in for example methylation (Meissner et al, 2008; Shen, 2006).  
 
2.6 METHODS OF ANALYZING DNA METHYLATION 
Recent years have brought great advances in analyses of DNA methylation, introducing 
genome-wide technologies and shedding the limitations of locus-specific methods. 
DNA methylation analysis can be divided into three main classes: restriction enzyme 
digestion-based methods, affinity-based methods and bisulfite treatment-based 
methods. The out-put DNA from these three approaches can be analysed by microarray 
techniques or sequencing.  
 
Restriction enzyme-based techniques take advantage of methylation-sensitive enzymes, 
causing methylated sequences to be protected against digestion. Affinity-based 
methods use antibodies specific for 5mC (MeDIP) or methyl-binding domains to pull 
down methylated regions. In bisulfite-based methods, the DNA is initially treated with 
bisulfite, converting unmethylated cytosines to uracil and thereby to thymine in 
subsequent PCR amplification steps. Some methods combine these approaches, such as 
reduced representation bisulfite sequencing (RRBS). This method uses DNA digestion, 
in this case with a methylation-insensitive enzyme with a CpG-containing recognition 
sequence, to enrich the sample for high CpG areas (Meissner, 2005). 
 
As with all methods, these approaches have strengths and weaknesses. Notably, most 
methods only accurately assess high/moderate density CpG areas. Both restriction 
enzyme- and affinity-based methods lack coverage in low CpG areas. In addition, 
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affinity-based methods give the relative methylation degree of a region, but do not 
identify methylation status of specific CpGs. The best coverage is offered by whole 
genome bisulfite sequencing (WGBS). However, this method requires extensive 
sequencing, leading to high costs. This problem has been circumvented in RRSB by 
using initial endonuclease digestion, to enrich for high-CpG areas, offering excellent 
coverage of these regions, but as mentioned failing to analyze low-CpG regions. 
 
2.6.1 The 450k array 
The Infinium HumanMethylation450 beadchip, or 450k array, from Illumina offers an 
affordable alternative to WGBS. It covers more than 480000 cytosines in the human 
genome with base pair resolution. Although probing fewer CpGs than methods such as 
RRBS, it is not dependent on CpG density and includes sites in and near CGIs as well 
as in low-CpG areas (Bibikova et al, 2011).  
 
The 450k platform is a bead array that requires bisulfite treated PCR-amplified DNA as 
input. The sample is hybridized to the array and a single base extension causes 
incorporation of a fluorophore. There are two types of probes on the array. The 
Infinium I probes, used for earlier methylation arrays, use two separate probes for each 
site, bridging the target CpG; one corresponding to the methylated sequence (ending 
with CG) and one corresponding to the unmethylated sequence (ending with CA to be 
complementary to CpT resulting from bisulfite conversion). The probe is used as a 
primer to perform incorporation of a fluorophore marked base complementary to the 
next base in the target DNA. For Infinium II probes, the probe sequence ends between 
the C and G of the target CpG, and the methylated or unmethylated state is determined 
by which base is incorporated. For both probe types the ratio of methylation to total 
signal (methylated/(methylated+unmethylated)) can be expressed as a β-value, 
representing the ratio of cells in which the site is methylated. 
 
A weakness of bisulfite-based methods, such as WGBS and the 450k array, is the 
inability to distinguish between 5mC and 5hmC, which are both protected against 
conversion to uracil by bisulfite treatment. However, several methods have already 
been developed to circumvent this problem (Rivera & Ren, 2013). 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I: GENOME-WIDE MAPPING OF HISTONE MODIFICATIONS 
AND MASS SPECTROMETRY REVEAL H4 ACETYLATION BIAS AND 
H3K36 METHYLATION AT GENE PROMOTERS IN FISSION YEAST  
In paper I we investigated patterns and coexistence of histone modifications in the 
fission yeast S. pombe to gain insight into effects of modification combinations and 
their relationship to gene expression. We employed two powerful and complementary 
techniques. Using ChIP-on-chip with antibodies specific for 12 histone modifications, 
we could assess the genomic distribution of marks with regard to each other and to 
genes. However, ChIP does not address the coexistence of histone modifications on the 
same histone molecule. To this end we used quantitative mass spectrometry (MS) and 
detected 10 acetylation sites as well as H3K36, H3K4, H3K9 and H4K20 mono-, di-, 
and tri-methylation. To elucidate the relationship between histone modifications and 
gene expression we performed transcriptome profiling using expression microarrays.  
 
Comparing the occupancy of histone modifications in promoter regions of genes, we 
found that H3 acetylation marks had the best correlation with each other, as did H4 
acetylation marks. In general, histone acetylation in the promoter region correlated with 
transcription, as expected. The correlation was stronger for H3 acetylation than for H4 
acetylation, in particular for H3K18ac, H3K9ac and H3K27ac. Similar results were 
obtained for open reading frames (ORFs). 
 
Clustering genes based on the pattern of histone modifications in their promoters 
produced 31 clusters. Gene ontology analysis revealed that 29 of these clusters were 
enriched for at least one functional term. Further grouping could divide the clusters into 
4 groups based on similarity, where each group showed unique characteristics. For 
example, group I had high H3K36me2 and low H3ac, while group III had high 
H3K27ac and low H3K36me2. Interestingly, clusters of the same group were often 
linked to similar functional categories. These results indicate that, in S. pombe, genes 
with similar functions share common patterns of histone modifications in the promoter. 
 
Clustering ORFs based on H4 acetylation indicated a preference for core-proximal 
lysine acetylation, where genes that had the distal H4K5ac, usually had the other sites 
acetylated as well, and genes that had H4K8ac had high levels of K12ac and K16ac. 
MS results confirmed that the acetylation bias was true also on single histones peptides.  
Similar observations have been made in human cells as well as mouse brain and called 
a H4 acetylation zip (Turner et al, 1989; Zhang et al, 2002; Tweedie-Cullen et al, 
2012). Comparing H4 acetylation on genes with different length, we observed that 
shorter genes tended to have several of the H4 lysines acetylated, whereas longer genes 
often had only K16ac. Furthermore, genes with 3-4 H4 lysines acetylated had higher 
average expression than genes with only K16ac. Our results demonstrate a H4 
acetylation zip in fission yeast as well as a connection between H4 acetylation in ORFs 
and transcription levels. 
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Previous studies have demonstrated that methylation of H3K4 and H3K36 affects 
histone acetylation in budding yeast. H3K4 methylation by the KMT Set1p recruits 
KATs causing H3K4 trimethylated histones to be highly acetylated (Jiang et al, 2007; 
Taverna et al, 2006). In contrast, Set2p associates with the phosphorylated CTD of 
elongating pol II and methylates H3K36, which recruits the HDAC Rpd3p causing 
deacetylation of the ORF (Carrozza et al, 2005). To test if the same crosstalk exists in 
fission yeast, we analysed histone acetylation levels with MS in set1 and set2 mutant 
strains. As predicted, acetylation levels on both H3 and H4 were decreased in the set1Δ 
background and increased in the set2Δ background, confirming that H3 methylation is 
involved in regulation of histone acetylation. 
 
When comparing histone modification levels in promoter regions, the lowest 
correlation was observed for H3K27ac and H3K36me2. This prompted us to 
investigate the relationship between these two modifications on the same histone 
peptide with MS. The results showed a clear antagonistic relationship between 
H3K36me2/3 and H3K27ac. Furthermore, H3K27ac levels were elevated in the set2Δ 
background, consistent with H3K36me recruitment of HDAC activity.  
 
Because H3K36me recruits the HDAC Rpd3p in budding yeast, we next looked at 
H3K27ac levels in a strain with mutated clr6, the fission yeast ortholog of rpd3. 
Indeed, global levels of H3K27ac were elevated in the clr6-1 strain. To address the 
potential significance of the observed K27ac/K36me crosstalk at promoters, we looked 
at expression of the previously identified gene clusters in the set2Δ strain relative to 
wild type cells. Interestingly, whereas most clusters showed some degree of increased 
expression, the two most upregulated clusters belonged to group 1, which had high 
H3K36me2 in wild type cells. In contrast, set1Δ caused a general downregulation of 
expression. Collectively, this demonstrates crosstalk between H3K27ac and H3K36me 
with a potentially regulatory role at gene promoters in S. pombe. 
 
In summary, in paper I we showed that H3 acetylation correlates with transcription, in 
particular acetylation of lysines K9, K18 and K27, and that genes with similar function 
share common histone modification patterns in the promoter region. H4 acetylation in 
S. pombe follows a zip model, with bias for core-proximal sites. Genes with several H4 
sites acetylated in the ORF tend to have higher expression than monoacetylated genes. 
We also describe crosstalk between H3 methylation and histone acetylation. H3K36 
methylation was found at promoters of genes and showed an antagonistic relationship 
with K27ac, possibly through recruitment of the HDAC Clr6. 
 
3.2 PAPER II: HIGH-THROUGHPUT TRANSCRIPTION PROFILING 
IDENTIFIES PUTATIVE EPIGENETIC REGULATORS OF 
HEMATOPOIESIS 
Many chromatin-modifying factors have lineage or cell specific functions in 
hematopoiesis, as discussed in section 1.9. Despite this, there are no studies with 
comprehensive analysis detailing expression patterns of epigenetic factors in blood 
cells. For dependable and comparable results across cell types, expression using the 
same methodology needs to be co-analysed. In paper II we took advantage of the vast 
number of cell types analysed by CAGE in the FANTOM 5 consortium and set out to 
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create a map of the expression of an extensive list of chromatin modifiers and accessory 
subunits. 
 
RLE normalized CAGE data was obtained for mature blood cells as well as for 
stem/progenitor cells, and expression data for 199 chromatin modifiers was extracted 
for analysis. Clustering of the cell types and replicates, as well as PCA analysis, largely 
separated the myeloid from the lymphoid lineage, and also separated progenitor cells. 
The two dendritic subtypes, myeloid and lymphoid, clustered with their lineage of 
origin, indicating some level of epigenetic memory of descent.  
 
We divided the genes into six functional groups based on their involvement in DNA 
methylation, histone acetylation/deacetylation, histone methylation/demethylation or 
chromatin remodeling. Heatmap analysis revealed several interesting patterns. Some 
genes are relatively evenly expressed, such as HDAC1 and HDAC2, indicating a 
ubiquitous role in hematopoiesis. However, many genes show differential expression 
between cell types. DNMT3B, for example, is only expressed in progenitor cells, in 
line with previous studies (Mizuno, 2001; Xie et al, 1999), whereas DNMT1 levels are 
generally higher in most lymphoid cells than in myeloid cells. 
 
Interestingly, expression of specific BAF complex subunits was both variable and cell 
type specific. Out of the two possible ATPase subunits, SMARCA2 was significantly 
more highly expressed compared to SMARCA4 in most cell types. BAF53A 
(ACTL6A) was low in most cell types, but very abundant in progenitor cells, in 
agreement with requirement of this protein in HSCs (Krasteva et al, 2012). In contrast, 
BAF45C (DPF3) was exclusively expressed in B cells, while BAF60C (SMARCD3) 
was present in a subset of myeloid cells. These results point to the existence of BAF-
complexes with different subunit composition in hematopoietic cells, which may be 
involved in control of cell type specific genes and differentiation, as observed in other 
tissues (see section 1.4). 
 
Next, we used edgeR analysis to search our data set for chromatin modifiers that were 
differentially expressed between the myeloid and the lymphoid lineages. We found that 
the two histone chaperones ASF1B and JDP2 are only expressed in myeloid cells. 
Several other factors, such as the CRC components CHD3 and INO80D, as well as  
MLL, KDM2B and the bromodomain protein ATAD2 have significantly higher 
transcription rates in lymphoid than in myeloid cells. These factors may therefore be 
involved in establishing lineage choice and identity. 
 
We also included CAGE data from 21 leukemic cell lines in our analysis. PCA results 
demonstrated that the leukemic cells cluster together with progenitor cells, separate 
from mature blood cells. However, we identified several genes that showed differential 
expression between malignant cells and normal blood cells, including progenitors. 
SMARCA4 and the PRC1 component CBX8 are both overexpressed in leukemic cells. 
In contrast, the chromatin remodeler CHD2 and another PRC1 factor, EPC1, are 
significantly more lowly expressed in leukemic cells compared to normal blood cells. 
CBX8 and EPC1 have previously been implicated in AML and ALL respectively (Tan 
et al, 2011a; Nakahata et al, 2009). CHD2 on the other had, has been found to be 
recurrently mutated in chronic lymphoid leukemia (Quesada et al, 2012).  
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Finally, we utilized the ability of CAGE to identify precise TSSs to search for genes 
with multiple TSSs that show differential use between cell types. We found that several 
genes had multiple active TSSs in blood cells, and in some cases the relative 
contribution between TSSs to total transcription differed between cells. For RBBP7, 
HDAC5 and CHRAC1, the dominant TSS was not the same in all cell types. For 
RBBP7, for example, we identified two TSSs, of which TSS1 was the preferred site in 
B cells, TSS2 the preferred site in myeloid dendritic cells, and some cells, such as 
CD8+ T cells, used both sites equally. Determining the biological consequences of 
alternative TSS use requires experimental validation, but it could possibly reflect 
differences in transcriptional regulation. 
 
In conclusion, the results from paper II include identification of differential expression 
of multiple chromatin modifiers in the hematopoietic system. The results from our 
analysis reveal expression of epigenetic factors that is specific for cell types, lineages 
and leukemic cells, indicating possible roles for numerous factors in control of 
differentiation and lineage commitment. In addition, we identified differential use of 
alternative TSSs between cell types. This comprehensive expression map of chromatin 
modifiers in blood cells can hopefully serve as a foundation for functional 
characterization of the role of specific factors in hematopoiesis. 
 
3.3 PAPER III: ANALYSIS OF THE DNA METHYLOME AND 
TRANSCRIPTOME IN GRANULOPOIEIS REVEAL TIMED CHANGES 
AND DYNAMIC ENHANCER METHYLATION 
As discussed in section 1.9.1, DNA methylation is clearly important for making the 
choice between myeloid and lymphoid lineage commitment. In paper III we aimed to 
gain further insight into changes of DNA methylation patterns in granulopoiesis. We 
used bone marrow from healthy human donors and FACS to isolate granulopoietic cell 
populations at four different differentiation stages, namely CMP, GMP, PMC 
(promyelocytes and myelocytes) and PMN (including metamyelocytes, band cells and 
mature neutrophils). The methylome of these cell populations was analysed using the 
Infinium 450k array. We also performed transcriptome profiling using both expression 
arrays and CAGE. This analysis produced a genome-wide map of methylation and 
expression changes at high cellular resolution, ranging from the multipotent CMP to 
mature bone marrow neutrophil, allowing us to pinpoint the stage at which changes 
occur in granulopoietic differentiation. 
 
By comparing β-values (defined as the ratio of methylation for a specific CpG site) 
between the four cell types, we identified 10156 differentially methylated sites (DMSs) 
during granulopoiesis. A majority of these sites showed decreased methylation (8973 
DMSs), while a smaller set gained methylation (930 DMSs). Interestingly, a small set 
of sites (253 DMSs) showed changes in both directions between different stages. 
Plotting of DMSs between consecutive cell stages made it abundantly clear that 
changes were not uniform over time, but occurred at specific stages. Most of the 
increases were between CMP and GMP, whereas the major decrease happened between 
GMP and PMC. Therefore, the major methylation changes occur at points of lineage 
restriction, suggesting a role in control of cell fate.  
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Examining the genomic distribution of DMSs we found that, in agreement with 
previous work, changes were greatly underrepresented in CGIs (Ji et al, 2010). 
However, we did not observe any overrepresentation of DMSs in CpG island shores (0-
2 kb from CGI). Instead, DMSs were enriched in the shelf (2-4 kb from CGI) and the 
open sea regions (>4kb from CGI).  
 
Gene ontology analysis was performed on differentially expressed genes. As could be 
expected, the list of genes upregulated during granulopoietic differentiation was 
enriched for functional terms relating to neutrophil function and defence responses. 
Correspondingly, for downregulated genes the terms included functions in cell division, 
biosynthesis and DNA replication reflecting terminal differentiation. Comparing the 
expression and DNA methylation data, we found that there was a significant overlap 
between upregulated genes and genes with decreased DNA methylation, and vice 
versa. This result agrees with the generally repressive nature of DNA methylation. 
Upon closer examination of several known granule genes, it was clear that the change 
in DNA methylation was concomitant with, and opposite to, the change in gene 
expression. Importantly, we confirmed this trend at several key hematopoietic 
transcription factor genes, including PU.1, GATA2 and GFI1. Furthermore, the changes 
in DNA methylation and expression of these transcriptional regulators was 
accompanied by a corresponding change in motif activity. The motif activity reflects 
the transcription levels of genes with consensus binding sites for a particular 
transcription factor. This indicates that DNA methylation is involved in controlling the 
transcriptional network that governs hematopoiesis. 
 
The 450k array probes are annotated for location in chromatin-defined enhancers. 
Comparing β-value variation across samples for all probes on the array showed that 
there was greater DNA methylation variability in enhancers than in the rest of the 
genome. This was supported by the overrepresentation of enhancer-annotated probes in 
the DMS list.  
 
To further explore the role of DNA methylation in enhancers during granulopoiesis, we 
used a new CAGE-based method for enhancer annotation. This method, developed by 
Andersson et al (2014), is founded on the observation that enhancers are flanked by 
divergent transcription, and the expression of enhancers is proportional to enhancer 
activity. When we examined the overlap between DMSs and enhancers active in 
CD34+ cells compared to neutrophils and vice versa, we found that DMSs are 
significantly enriched in neutrophil specific enhancers, but not in progenitor specific 
enhancers. As most of the DMSs showed decreased methylation, this indicated that 
enhancer demethylation correlates with activation. Indeed, enhancers with decreasing 
DMSs showed increased transcription. Importantly, expression of downstream genes 
also increased, suggesting that DNA methylation is involved in regulating 
differentiation induced enhancer activation, and thereby transcription of downstream 
target genes.  
 
To summarize, we characterized the methylome and transcriptome in granulopoiesis 
using high cellular resolution, which allowed us to closely define when in 
differentiation changes occur. We found that there is a general demethylation of 
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granulopoietic cells, and that changes in methylation occur at specific time points in 
conjunction with lineage restriction. Changes were most common in regions distant to 
CGIs and reciprocal to changes in transcription. Importantly DNA methylation may 
control expression of key hematopoietic transcription factors. Finally DNA methylation 
is dynamic in enhancer elements and may be involved in controlling the activity of 
these cis-regulatory elements during differentiation. 
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4 CONCLUDING REMARKS 
This thesis has aimed to clarify the functions and consequences of epigenetic 
mechanisms on a large scale, with focus of their involvement in hematopoiesis. In 
paper I we used the fission yeast S. pombe as a model system to investigate 
combinatorial patterns of histone modifications. We demonstrated that there are 
specific modification patterns associated with genes of particular functions. We also 
demonstrated several cases of histone modification crosstalk. These results highlight 
the importance of taking a larger, more comprehensive picture into account when 
studying chromatin biology. As discussed in the introduction, epigenetics is rarely 
about a single factor or mark, but more accurately about interdependent networks.  
 
This is the reason why studies such as paper II are both interesting and important. By 
examining the expression of a wide range of chromatin modifiers, we could identify 
cell, lineage and cancer specific epigenetic factors, suggesting a role for these proteins 
in blood development. Although experimental validation of their precise function in 
hematopoiesis is required, it provides the groundwork for identifying combinations of 
chromatin modifiers essential and characteristic for differentiation of different blood 
lineages, which would potentially reflect the epigenomes of these cells. 
 
In paper III we zoomed in on granulocyte development and analyzed DNA methylation 
and gene expression of closely related cell populations representing different stages of 
granulopoiesis. We found that DNA methylation changes predominantly consist of 
decreases in granulpoiesis, and that changes occur at specific time points. Whereas 
decreased DNA methylation in neutrophil development has been described elsewhere 
(Ji et al, 2010; Hodges et al, 2011; Bocker et al, 2011), previous studies lacked the 
high cellular resolution to ascertain exactly when changes occur.  
 
An interesting question is whether the observed demethylation is a result of active or 
passive mechanisms. Cells around the GMP stage, where the decrease is most obvious, 
are highly proliferative and CAGE data from paper II indicated that DNMT1 is 
somewhat more weakly expressed in a subset of myeloid cells, including neutrophils, 
possibly arguing for passive demethylation.  
 
Still, considering the high incidence of TET2 and IDH1/2 mutations in AML with 
accompanying hypermethylation (discussed in section 1.9.4.1), it would be of interest 
to evaluate whether the DNA demethylation in granulopoiesis is mediated by TET2 and 
hydroxymethylation. Unfortunately, the TET enzymes were not included in our 
expression analysis in paper II and one of the weaknesses of the 450k array is the 
inability to distinguish methylation from hydroxymethylation. If demethylation was 
preceded by hydroxymethylation it would argue strongly for active demethylation. 
 
450k array analysis of granulopoiesis revealed that DNA methylation is especially 
dynamic in enhancer elements. Importantly, decreased enhancer methylation 
overlapped with increased enhancer activity and expression of downstream genes. 
Since enhancers are preferably located in CpG poor areas (Andersson et al, 2014)  and 
the 450k array lacks complete coverage in the genome, many enhancer regions are only 
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represented by a single probe. It may be relevant to investigate the methylation status of 
the surrounding region to address whether the methylation change has site-specific 
effects or reflects the overall chromatin state of that region. The recent discovery of 
super-enhancers, extensive enhancer clusters involved in regulation of cell fate (Whyte 
et al, 2013; Lovén et al, 2013; Hnisz et al, 2013), creates new questions. It would be 
interesting to see if any of our demethylated enhancers reside in such clusters. Super-
enhancers are commonly associated with cell type specific genes. Indeed, among the 
genes controlled by the demethylated enhancers were genes relevant for neutrophil 
development and function such as cytokines and receptors for cytokines and growth 
factors. 
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